****

**Stockport CCG prescribing restriction lists**

The Stockport CCG Black and Grey Listing prevents prescribing of drugs deemed to be less suitable for prescribing due to safety, efficacy or of poor value for the NHS in line with the criteria used nationally.

Any product can be nominated for considered for listing by NHS Stockport clinicians or CCG staff. Products added to the Do Not Prescribe list produced by the GMMMG Formulary Group will automatically be added. Product considered by GMMMG for the Do Not Prescribe or grey list at a GM level will be reviewed locally, in case there is a different position locally. Amendments to the list can also be requested on this form.

Please send completed forms to: STOCCG.medsopadmin@nhs.net

Name of product(s) to be considered:

Reason for product nomination/ entry amendment (*attach additional evidence if necessary*):

**Criteria for Inclusion on the Stockport restricted prescribing lists**

1. Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety concerns;
2. Products which are clinically effective but where more cost-effective products are available, including products that have been subject to excessive price inflation; or
3. Products which are clinically effective but, due to the nature of the product, are deemed a low priority for NHS funding.
4. There is only a narrow, defined place for use of the drug/ preparation. (Such drugs will be grey listed to allow use within this defined situation). The specified situation suggested is

\* Whilst prescribers should think very carefully before prescribing or recommending any of the DNP products, there may be exceptional instances when the use of one of these products is necessary for a particular patient. A patient may be deemed exceptional if the patient has a clinical picture that is significantly different to the general population of patients with that condition and as a result of that difference the patient is likely to derive greater benefit from the intervention than might normally be expected for patients with that condition. Before prescribing clinicians should seek approval to prescribe from the CCG to ensure the CCG agrees the exceptionality and approves prescribing outside of the policy

Suggested Criteria for listing or change of listing 1 / 2 / 3 / 4 (grey list)

Approval process applicable: GMMMG listed / Brand multiplier (3x) / Pre-existing policy (automatic)

Panel decision (other than the above)

Date considered

Decision

Approved for Black Listing Yes/ No Category 1 / 2

Approved for Grey Listing Yes/ No

Criteria for permissible grey list use:

Outcome confirmed on behalf of STAMP (Chair of meeting / Director / Head of Service)

Signed: Designation: